The Oncology Institute, Inc.

STLN · NasdaqCM · Stock · Healthcare
$6.91
+6.14% today
Delayed price,

What The Oncology Institute does

Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.

Key facts

Sector
Healthcare
Industry
Medical Care Facilities
Market cap
$704.2M
P/E (ttm)
—
Forward P/E
—
Dividend yield
0.00%
Beta
0.42
Profit margin
-6.2%
Employees
641
Headquarters
Cerritos, CA, United States
Exchange
NasdaqCM

Performance

1 Month
-0.7%
3 Months
+29.2%
6 Months
+95.2%
1 Year
+80.9%
5 Years
+6.5%
$2.3252-week range$7.13
Biggest setback — last 12 months
-47.2%
20 Oct 2025 → 9 Feb 2026
Fell from $4.75 to $2.51 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+177.3%
9 Feb 2026 → 14 Sept 2026
Ran from $2.51 to $6.96 — its strongest sustained advance this year.

Price outlook — trend & volatility model

● Trend: Above long-term trend
Price sits above its 200-day average, but the shorter-term averages are not cleanly aligned above/below it.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$5.24 (-19.5%)$6.51$8.09 (+24.3%)
3 Months$4.47 (-31.4%)$6.51$9.49 (+45.7%)
6 Months$3.82 (-41.3%)$6.51$11.09 (+70.3%)
12 Months$3.07 (-52.9%)$6.51$13.82 (+112.3%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 75.3%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Recent insider activity

Sold 298,853 shares at $6.51 — Hively Brad, Director · 2026-08-24
Acquired 33,133 shares — Kaushal Mohit, Director · 2026-07-29
Acquired 41,165 shares — McGeorge Anne, Director · 2026-07-29
Acquired 30,120 shares — Pacala Mark L, Director · 2026-07-29
Acquired 31,124 shares — STOLPER MARK, Director · 2026-07-29
Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.